ONS ONCC Chemo Renewal
Exam 2026 Questions and
Answers (Verified
Answers by Expert)
Neoadjuvant therapy does not increase survival when compared to adjuvant
therapy. It only changes the timing of treatment and can change surgical options if
the tumor is shrunk enough. If this occurs, the patient may only require a
lumpectomy plus radiation therapy instead of needing a mastectomy - ANSWER-
Main benefit of neoadjuvant chemotherapy (breast cancer patient)
A comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation to
assess life expectancy and risk of morbidity and mortality in the older patient. This
assessment tool would evaluate and include the following areas: functional status,
socioeconomic issues, psychosocial distress, comorbidities, cognitive function,
nutritional status, polypharmacy, and a medication review (NCCN Older Adult
Oncology Guidelines, version 1.2015). - ANSWER-Due to Mrs. Turner's age and
comorbidities, her oncologist performs a comprehensive geriatric assessment. You
know that this assessment covers all but which of the following:
65 - ANSWER-The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides information on what is included in a comprehensive geriatric
assessment. Currently, more than 60% of cancers in the United States occur in
,people age ______and older and as the oncology world ages, nearly half (46%) of
cancer survivors are 70 years of age or older
Two of the agents (docetaxel and carboplatin) that Mrs. Turner will receive are
categorized as irritants. Docetaxel can cause a significant reaction if it
extravasates. It can lead to edema, erythema, occasional pain and blister
formation (ONS Chemo/Bio guidelines, 2014). That is the most likely reason that
Mrs. Turner was given a port for her treatments. Some patients will receive their
treatments through a peripheral IV without incident. Just because they are
intravenous agents does not mean that a port is required and needing a port has
nothing to do with her being older in age. Since none of these agents are
vesicants, they likely could have been given safely via peripheral route but having
a port placed is OK as well. - ANSWER-What is your best explanation for why Mrs.
Turner was given a port to receive her chemotherapy?
Irrirtants - ANSWER-_____________can cause inflammation, pain, and burning
but rarely cause tissue necrosis comparable to a vesicant (unless a large amount
or a very high concentration of the irritant is extravasated).
Vesicants - ANSWER-_____________can cause blistering and significant pain and
tissue damage and destruction, leading to tissue death.
Non-DNA-binding solutions remain in the local area of the extravasation, which
improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the antagonist to be
ingested cellularly, leading to progressive tissue destruction - ANSWER-A further
classification of an antineoplastic agent's potential to cause damage is whether its
mechanism of action includes DNA binding.
, Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin - ANSWER-DNA Binding Irritants
Amsacrine
Paclitaxel
Vinblastine
Vincristine
Vindesine
Vinorelbine - ANSWER-DNA Nonbinding vessicants
Sodium thiosulfate
Inject 2 ml of sodium thiosulfate for each milligram of
mechlorethamine extravasated.
Inject subcutaneously into extravasation site using a 25
gauge or smaller needle (change needle with each injection).
Exam 2026 Questions and
Answers (Verified
Answers by Expert)
Neoadjuvant therapy does not increase survival when compared to adjuvant
therapy. It only changes the timing of treatment and can change surgical options if
the tumor is shrunk enough. If this occurs, the patient may only require a
lumpectomy plus radiation therapy instead of needing a mastectomy - ANSWER-
Main benefit of neoadjuvant chemotherapy (breast cancer patient)
A comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation to
assess life expectancy and risk of morbidity and mortality in the older patient. This
assessment tool would evaluate and include the following areas: functional status,
socioeconomic issues, psychosocial distress, comorbidities, cognitive function,
nutritional status, polypharmacy, and a medication review (NCCN Older Adult
Oncology Guidelines, version 1.2015). - ANSWER-Due to Mrs. Turner's age and
comorbidities, her oncologist performs a comprehensive geriatric assessment. You
know that this assessment covers all but which of the following:
65 - ANSWER-The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides information on what is included in a comprehensive geriatric
assessment. Currently, more than 60% of cancers in the United States occur in
,people age ______and older and as the oncology world ages, nearly half (46%) of
cancer survivors are 70 years of age or older
Two of the agents (docetaxel and carboplatin) that Mrs. Turner will receive are
categorized as irritants. Docetaxel can cause a significant reaction if it
extravasates. It can lead to edema, erythema, occasional pain and blister
formation (ONS Chemo/Bio guidelines, 2014). That is the most likely reason that
Mrs. Turner was given a port for her treatments. Some patients will receive their
treatments through a peripheral IV without incident. Just because they are
intravenous agents does not mean that a port is required and needing a port has
nothing to do with her being older in age. Since none of these agents are
vesicants, they likely could have been given safely via peripheral route but having
a port placed is OK as well. - ANSWER-What is your best explanation for why Mrs.
Turner was given a port to receive her chemotherapy?
Irrirtants - ANSWER-_____________can cause inflammation, pain, and burning
but rarely cause tissue necrosis comparable to a vesicant (unless a large amount
or a very high concentration of the irritant is extravasated).
Vesicants - ANSWER-_____________can cause blistering and significant pain and
tissue damage and destruction, leading to tissue death.
Non-DNA-binding solutions remain in the local area of the extravasation, which
improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the antagonist to be
ingested cellularly, leading to progressive tissue destruction - ANSWER-A further
classification of an antineoplastic agent's potential to cause damage is whether its
mechanism of action includes DNA binding.
, Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin - ANSWER-DNA Binding Irritants
Amsacrine
Paclitaxel
Vinblastine
Vincristine
Vindesine
Vinorelbine - ANSWER-DNA Nonbinding vessicants
Sodium thiosulfate
Inject 2 ml of sodium thiosulfate for each milligram of
mechlorethamine extravasated.
Inject subcutaneously into extravasation site using a 25
gauge or smaller needle (change needle with each injection).
